Kelun-Biotech (6990.HK)

https://kelun-biotech.com/.

Kelun Biotech is a clinical-stage biotech company established in 2016, a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd, engaged in biologic therapeutics as well as small molecule discovery and development. The company focuses on unmet medical needs such as oncology and autoimmune conditions and strives to be a leader in novel therapeutic discovery and development. Since its inception, Kelun-Biotech has established multi-modal drug discovery platforms based on global standards and made important development breakthroughs in antibody-drug conjugation, immuno-oncology, bispecific antibody and novel small molecule targeting and designs. Kelun-Biotech’s current pipeline includes 33 therapeutic programs for the treatment of cancers, autoimmune conditions, infectious diseases, and metabolic syndromes. Fourteen programs are in clinical development in China, two of which have entered into clinical development in the US. Most notably, Kelun-Biotech has built out a proprietary ADC platform which is protected by a complex patent portfolio. Our comprehensive ADC capabilities range from novel target discovery, payload screening, linker design, as well as GMP manufacturing. As of today, Kelun-Biotech is advancing over 10 novel ADC programs in varying stages of development. *

	Start	2016-01-01 established
	Group	Kelun Pharmaceutical (Group)
	Industry	biopharmaceutical
	Industry 2	antibody-drug conjugate (ADC)

	City	n. a.
		Address record changed: 2025-01-11

Basic data	Employees	n. a.

		* Document for »About Section«: Merck & Co., Inc.. (12/22/22). "Press Release: Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer". Rahway, NJ.

		Record changed: 2025-03-16

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x200px

More documents for Kelun Pharmaceutical (Group)

[1] Windward Bio AG. (1/10/25). "Press Release: Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]